التفاصيل البيبلوغرافية
| العنوان: |
OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. |
| المؤلفون: |
Gaspar, Nathalie, Campbell-Hewson, Quentin, Huang, Jie, Okpara, Chinyere E, Bautista, Francisco |
| المصدر: |
Future Oncology; Oct2021, Vol. 17 Issue 32, p4249-4261, 13p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, ETOPOSIDE, QUINOLINE, RESEARCH, UREA, CLINICAL trials, PROTEIN kinase inhibitors, OSTEOSARCOMA, RESEARCH methodology, IFOSFAMIDE, EVALUATION research, BONE tumors, COMPARATIVE studies, RANDOMIZED controlled trials, QUALITY of life |
| مستخلص: |
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II study in patients with relapsed/refractory osteosarcoma. This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma. The primary end point is progression-free survival; secondary and exploratory end points include, but are not limited to, overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
